Literature DB >> 7814888

Complement component C7 is a plasminogen-binding protein.

J Reinartz1, G M Hänsch, M D Kramer.   

Abstract

Ab deposition, whether by reaction with the specific Ag or by preformed immune complexes, is followed by activation and deposition of complement components. Tissue destruction is observed in the Ab- and complement-induced lesions. The proteolytic enzyme plasmin is thought to participate in the Ab- and complement-mediated organ pathology. Plasmin is generated from plasma-derived plasminogen by cell-derived plasminogen activators (PAs). Two types of PAs are known, urokinase-type PA (uPA) and tissue-type PA (tPA). We investigated whether the PA system and the complement system can interact to promote local plasmin generation. Among the terminal complement components C5b6, C7, C8, and C9, the nonenzymatic component C7 is a plasminogen-binding protein. Radioligand binding studies revealed that the isolated component, as well as C7 after its incorporation into the terminal complement complex C5b-9, can bind plasminogen. Binding was inhibited by the lysine analogues 6-aminohexanoic acid and tranexamic acid, implicating the lysine binding sites of plasminogen into the binding interaction. tPA-mediated plasminogen activation was enhanced in the presence of C7. Based on these findings, an interaction is proposed between the complement system and the plasminogen activator system; a mechanism that may focus plasmin activity to structures that have been tagged by Ab and complement deposition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7814888

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Modulation of complement membrane attack by local C7 synthesis.

Authors:  R Würzner
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

2.  Dengue-2 structural proteins associate with human proteins to produce a coagulation and innate immune response biased interactome.

Authors:  Brenda B Folly; Almeriane M Weffort-Santos; C G Fathman; Luis R B Soares
Journal:  BMC Infect Dis       Date:  2011-01-31       Impact factor: 3.090

3.  The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria.

Authors:  Theresa N Ramos; Meghan M Darley; Sebastian Weckbach; Philip F Stahel; Stephen Tomlinson; Scott R Barnum
Journal:  J Biol Chem       Date:  2012-06-11       Impact factor: 5.157

4.  Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial.

Authors:  Juan J Jiménez; José L Iribarren; Maitane Brouard; Domingo Hernández; Salomé Palmero; Alejandro Jiménez; Leonardo Lorente; Patricia Machado; Juan M Borreguero; José M Raya; Beatriz Martín; Rosalía Pérez; Rafael Martínez; María L Mora
Journal:  J Cardiothorac Surg       Date:  2011-10-14       Impact factor: 1.637

5.  Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response.

Authors:  Antoine Obry; Julie Hardouin; Thierry Lequerré; Frédérique Jarnier; Olivier Boyer; Patrice Fardellone; Peggy Philippe; Christian Marcelli; Xavier Le Loët; Olivier Vittecoq; Pascal Cosette
Journal:  Theranostics       Date:  2015-08-09       Impact factor: 11.556

6.  Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study.

Authors:  Juan J Jimenez Rivera; Jose L Iribarren; Jose M Raya; Ibrahim Nassar; Leonardo Lorente; Rosalia Perez; Maitane Brouard; Jose M Lorenzo; Pilar Garrido; Ysamar Barrios; Maribel Diaz; Blas Alarco; Rafael Martinez; Maria L Mora
Journal:  J Cardiothorac Surg       Date:  2007-04-10       Impact factor: 1.637

Review 7.  Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis.

Authors:  Meike Heurich; Melanie Föcking; David Mongan; Gerard Cagney; David R Cotter
Journal:  Mol Psychiatry       Date:  2021-07-05       Impact factor: 15.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.